

Notice of References Cited

Application/Control No.

09/214,836

Applicant(s)/Patent Under
Reexamination
FIGDOR ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 1 of 5

U.S. PATENT DOCUMENTS

*		Document Number	Date	Name	Classification	
		Country Code-Number-Kind Code	MM-YYYY			
	A	US-5,844,075-A	12-1998	Kawakami, Y, et al	530	326
	B	US-				
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number	Date	Country	Name	Classification	
		Country Code-Number-Kind Code	MM-YYYY				
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ezzell, C, 1995, Cancer "vaccines": an idea whose time has come?, Journal of NIH Research, vol. 7, pp. 46-49
	V	Bodey, B, et al, 2000, Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, vol. 20, pp. 2665-2676
	W	Zaks, TZ, et al, 1998, Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, vol. 58, pp. 4902-4908
	X	Lee, K-H, et al, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, vol. 163, pp. 6292-6300

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

J Rawlings
SR 9/7/01

Notice of References Cited	Application/Control No. 09/214,836	Applicant(s)/Patent Under Reexamination FIGDOR ET AL.	
	Examiner Stephen L. Rawlings, Ph.D.	Art Unit 1642	Page 2 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Boon, T, 1992, Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, Vol. 58, pp. 177-210
	V	Splitler, LE, 1995, Cancer vaccines: the interferon analogy, Cancer Biotherapy, Vol. 10, No. 1, pp. 1-3
	W	Cox, AL, et al, 1994, Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, vol. 264, pp. 716-719.
	X	Arceci, RJ, 1998, The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, vol. 76, pp. 80-93

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
9/7/01

Notice of References Cited

Application/Control No.

09/214,836

Applicant(s)/Patent Under
Reexamination
FIGDOR ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 3 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Gao, P, et al, 2000, Tumor vaccination that enhances antitumor T-cell responses does not inhibit th growth of established tumors, Journal of Immunotherapy, Vol. 23, No. 6, pp. 643-653.
	V	Hu, X, et al, 1996, Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, Vol. 56, pp. 2479-2483.
	W	Jaeger, E, et al, 1996, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, Vol. 66, No. 2, pp. 162-169.
	X	Mukherji, B, et al, 1995, Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, Proceedings of the National Academy of Science USA, Vol. 92, pp. 8078-8082.

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
9/7/01

Notice of References CitedApplication/Control No.
09/214,836Applicant(s)/Patent Under
Reexamination
FIGDOR ET AL.Examiner
Stephen L. Rawlings, Ph.D.Art Unit
1642

Page 4 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Timmerman, JM, et al, 1999, Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, vol. 50, pp. 507-529
	V	de Vries, TJ, et al, 1997, Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanom cell lines and in human melanocytic lesions, Cancer Research, vol. 57, No. 15, pp. 3223-3229.
	W	Slingluff, CL, et al, 2000, Melanomas with concordant loss of multiple differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, Cancer Immunology & Immunotherapy, Vol. 48, No. 12, pp. 661-672.
	X	Yamshchikov, G, et al, 2001, Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations, Clinical Cancer Research, Vol. 7, No. 3 supplement, pp. 909s-916s.

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
9/7/01

Notice of References Cited	Application/Control No. 09/214,836	Applicant(s)/Patent Under Reexamination FIGDOR ET AL.	
	Examiner Stephen L. Rawlings, Ph.D.	Art Unit 1642	Page 5 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Gura, T, 1997, Systems for identifying drugs are often faulty, Science, vol. 278, pages.1041-1042.
	V	Sinkovics, JG, et al, 2000, Vaccination against human cancers (review), International Journal of Cancer, vol. 16, pp. 81-96.
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
9/7/01